"Your health and safety are always our top priority. To help you protect yourself and your loved ones, we’ve gathered the most important information and guidance on the coronavirus and COVID-19. Go to our website. You have many ways to get care without leaving the comfort of your home - including an e-visit, phone, video appointments and email. This allows you to still get great care while helping to address the community spread of COVID-19. To book an in-person appointment, or if you’re concerned about your specific health condition, visit our website for your local information on appointments and 24/7 advice."

During the past decade, Kaiser Permanente-Modesto conducted 89 clinical trials. In the 10-year time frame, 89 clinical trials started and 40 clinical trials were completed, i.e. on average, 44.9% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 31 clinical trials were completed. i.e. 114.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kaiser Permanente-Modesto" #1 sponsor was "National Cancer Institute (NCI)" with 50 trials, followed by "SWOG Cancer Research Network" with 26 trials sponsored, "Alliance for Clinical Trials in Oncology" with 17 trials sponsored, "NRG Oncology" with 9 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 9 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kaiser Permanente-Modesto" #1 collaborator was "National Cancer Institute (NCI)" with 67 trials as a collaborator, "NRG Oncology" with 12 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator, "Medivation, Inc." with 2 trials as a collaborator and "Agenus Inc." with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Kaiser Permanente-Modesto" are "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Invasive Breast Carcinoma" (6 trials), "Stage II Breast Cancer" (6 trials) and "Stage IIIA Breast Cancer" (6 trials). Many other conditions were trialed in "Kaiser Permanente-Modesto" in a lesser frequency.

Most popular intervention types in "Kaiser Permanente-Modesto" are "Drug" (88 trials), "Other" (79 trials), "Biological" (46 trials), "Procedure" (35 trials) and "Radiation" (20 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (40 trials), "Quality-of-Life Assessment" (36 trials), "Questionnaire Administration" (21 trials), "Nivolumab" (18 trials) and "Biospecimen Collection" (16 trials). Other intervention names were less common.

The vast majority of trials in "Kaiser Permanente-Modesto" are 93 trials for "All" genders, 20 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Kaiser Permanente-Modesto". undefined are not yet recruiting, 30 are recruiting, 61 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Kaiser Permanente-Modesto, 4 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Kaiser Permanente-Modesto, 3 "Phase 1" clinical trials were conducted, 46 "Phase 2" clinical trials and 74 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".